Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks.

Saved in:
Bibliographic Details
Title: Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks.
Authors: Faust JS; Brigham and Women's Hospital Department of Emergency Medicine, Mass General Brigham Division of Health Services Research, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: jsfaust@bwh.harvard.edu.
Source: Journal of the American College of Cardiology [J Am Coll Cardiol] 2024 Oct 22; Vol. 84 (17), pp. 1643-1645. Date of Electronic Publication: 2024 Aug 30.
Publication Type: Editorial
Journal Info: Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8301365 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-3597 (Electronic) Linking ISSN: 07351097 NLM ISO Abbreviation: J Am Coll Cardiol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1558-3597
DOI:10.1016/j.jacc.2024.08.035